Trialbee has secured a majority growth investment from Varsity Healthcare Partners to support the expansion of its technology-driven patient recruitment services for global biopharma.

The Sweden-based company, which focuses on patient recruitment for clinical trials, said the investment will be used to accelerate growth across its Honey Platform, expand enterprise-level recruitment services, and strengthen its international delivery capabilities. Existing investors Industrifonden and MTIP will remain minority investors following the transaction.

The deal represents growth funding rather than clinical or regulatory news, and reflects increasing investor interest in infrastructure and technology addressing persistent patient recruitment challenges in clinical research.

Trialbee said the investment will allow it to scale its platform and services across multiple therapeutic areas and clinical programs, supporting sponsors and contract research organizations as trial designs become more complex and global.

Matt Walz, chief executive officer of Trialbee, said the company’s focus remains on improving access to clinical research for patients worldwide.

“Trialbee’s mission is to make clinical research more accessible for every patient, everywhere,” Walz said. “With Varsity as our majority partner — and continued support from Industrifonden and MTIP — we will scale our innovation with the Honey Platform, expand program-level recruitment to meet customer needs across entire pipelines, and deliver even greater predictability and speed for sponsors, CROs and sites worldwide.”

He added that the investment would support faster and more precise connections between patients and research sites, helping biopharma companies enrol trials more efficiently.

Over the past year, Trialbee has expanded its platform capabilities and global footprint. The company said it introduced sponsor-specific patient registries within its platform, strengthened data partnerships to support feasibility and enrolment projections, and screened more than 1.5 million patients in 2025. During that period, Trialbee worked with more than 6,000 research sites across 50 countries and supported trials in 66 languages.

Patient recruitment remains one of the most significant operational risks in clinical trials, with delays frequently leading to increased costs and extended timelines. As sponsors seek to improve predictability and execution across global studies, demand has grown for scalable recruitment infrastructure that integrates data, digital outreach, and site-level engagement.

Varsity Healthcare Partners invests in healthcare services and technology companies focused on enabling clinical operations at scale. The firm said its strategy centres on supporting management-led businesses with established platforms and strong operating foundations.

Navid Gharavi, partner at Varsity Healthcare Partners, said the firm views Trialbee as well positioned to address enrolment challenges facing the industry.

“We partner with founder- and management-led companies to build category leaders,” Gharavi said. “Trialbee combines deep patient understanding with a relentless focus on customer success and data-driven recruitment. We’re excited to support Matt and the team as they invest in product, analytics, and international growth—while continuing to deliver measurable enrollment impact for customers.”

Trialbee said its leadership team, culture and global delivery model will continue to guide the company as it scales to meet growing demand from biopharma sponsors and research partners.